Skip to content

Released May 11, 2023, after the close

10-Q filed May 11, 2023, 41 days after period end · 0001390478-23-000012

Q1 2023 · 10-Q
Revenue$0.00−100.0% vs Q1 2022no prior Q4 2022 on file
Net Income-$11.10MN/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.47N/M vs Q1 2022no prior Q4 2022 on file
Operating Income-$11,281,000N/M
Operating Cash Flow-$12,127,000N/M

What the release said

The release

Same quarter

MetricQ1 2023Q1 2022Q1 2021Q1 2020
Revenue$0.00$1.00M$5.70M$0.00
Net Income-$11.10M-$16.74M-$2.40M-$4.14M
EPS Diluted-$0.47-$1.05-$0.16-$0.66

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR